An announcement from Stoke Therapeutics ( (STOK) ) is now available.
On March 18, 2025, Stoke Therapeutics announced its financial results for 2024 and provided business updates, including the upcoming Phase 3 EMPEROR study of zorevunersen for Dravet syndrome. The company reported a strong financial position with $246.7 million in cash and anticipated funding from a Biogen collaboration to support operations until mid-2028. Dr. Edward M. Kaye will transition from CEO to an advisory role, and the company retains exclusive rights for zorevunersen in North America. Recent milestones, such as a Breakthrough Therapy Designation and positive data, have advanced their efforts in treating Dravet syndrome.
More about Stoke Therapeutics
Stoke Therapeutics, Inc. is a biotechnology company focused on restoring protein expression through RNA medicine. Their proprietary TANGO approach develops antisense oligonucleotides to selectively restore protein levels, with a primary focus on diseases of the central nervous system and the eye caused by haploinsufficiency. Their lead investigational medicine, zorevunersen, is in development for Dravet syndrome and is expected to enter Phase 3 development in 2025.
YTD Price Performance: -20.14%
Average Trading Volume: 805,808
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $455.5M
Find detailed analytics on STOK stock on TipRanks’ Stock Analysis page.